2. Search Result
Search Result
Results for "

AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG

" in MedChemExpress (MCE) Product Catalog:

58

Inhibitors & Agonists

57

Peptides

1

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Area
  • HY-P0165
    Taspoglutide

    ITM077; R1583; BIM51077

    		 GCGR Metabolic Disease
    Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM.
  • HY-P2136
    COG1410
    3 Publications Verification

    		 Apolipoprotein Apoptosis Neurological Disease Inflammation/Immunology
    COG1410 is an apolipoprotein E-derived peptide and an apoptosis inhibitor. COG1410 exerts neuroprotective and antiinflammatory effects in a murine model of traumatic brain injury (TBI). COG1410 can be used for the research of neurological disease .
  • HY-P2136F
    Biotin-COG1410 TFA

    		Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Biotin-COG1410 TFA is a biotin labled COG1410 (HY-P2136). COG1410 is an apolipoprotein E-derived peptide and an apoptosis inhibitor. COG1410 exerts neuroprotective and antiinflammatory effects in a murine model of traumatic brain injury (TBI). COG1410 can be used for the research of neurological disease .
  • HY-P10271
    RG7697

    NNC0090-2746; MAR709; RO6811135

    		 GLP Receptor Metabolic Disease
    RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
  • HY-P3637
    AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG

    		Peptides Inflammation/Immunology
    AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG promotes bone-ossification. AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG can be used in the research of diseases or disorders related to osteogenic defects or bone mineral density (BMD) decreasing, such as osteoporosis .
  • HY-P2098
    Alamethicin F 50

    		Antibiotic Bacterial Fungal Infection
    Alamethicin F 50 is an antibiotic. Alamethicin F 50 is composed of membrane-active peptide, containing 75% Alamethicin F 50/5 and 10% Alamethicin F 50/7. Alamethicin F 50 is exhibits antifungal and antibacterial activity by disrupting the integrity of microbial cell membranes, resulting in leakage of cell contents and death of the microorganisms. Alamethicin F 50 is able to reduce the surface tension of water, which can be used as a surfactant or detergent .
  • HY-P0165B
    Taspoglutide acetate

    ITM077 acetate; R1583 acetate; BIM51077 acetate

    		 GLP Receptor Metabolic Disease
    Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an Ki value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC50 = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .
  • HY-P3255
    DA-JC4

    		Insulin Receptor Neurological Disease Inflammation/Immunology
    DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways .
  • HY-P2429
    N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu

    		Opioid Receptor Others
    N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu is a compound that can antagonize the δ-opioid receptor and the action of [D-Pen2,D-Pen ] enkephalin in vivo. Its antagonistic effect can be verified by specific behavioral experiments.
  • HY-P10220
    NOTA-COG1410

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Others
    NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting radioligand for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography . NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P10031A
    SAR441255 TFA

    		GLP Receptor GCGR Metabolic Disease
    SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors.?SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .
  • HY-P10031
    SAR441255

    		GLP Receptor GCGR Metabolic Disease
    SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .
  • HY-108742A
    Abaloparatide TFA
    2 Publications Verification

    BA 058 TFA; BIM 44058 TFA

    		 Arrestin PTHR Metabolic Disease Endocrinology Cancer
    Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue. Abaloparatide TFA also is a selective PTHR1 activator. Abaloparatide TFA enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide TFA enhances bone formation and cortical structure in mice. Abaloparatide TFA has the potential for the research of osteoporosis .
  • HY-P10902
    Lorutengitide

    		DNA/RNA Synthesis Cancer
    Lorutengitide is a transcriptional regulatory peptide, and exhibits antiproliferative efficacy .
  • HY-108742
    Abaloparatide
    2 Publications Verification

    BA 058; BIM 44058

    		 PTHR Arrestin Metabolic Disease Cancer
    Abaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis .
  • HY-P10302A
    GLP-1R/GIPR agonist-1 (soduim)

    		GLP Receptor Metabolic Disease
    GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC50 is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC50 is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
  • HY-P11270
    Relsipatide

    BG128

    		 Insulin Receptor GLP Receptor Metabolic Disease
    Relsipatide (BG128) is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .
  • HY-P10302
    GLP-1R/GIPR agonist-1

    		GLP Receptor Insulin Receptor Metabolic Disease
    GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
  • HY-101230
    ICI 174864

    		Opioid Receptor Neurological Disease
    ICI 174864 is a highly selective, potent δ-receptor antagonist. ICI 174864 is equipotent with naloxone and can not reverse the effect of the μ-agonist [D-Ala2, MePhe4, Gly-Ol5]enkephalin or the κ-agonist-tifluadom .
  • HY-153476
    GIP/GLP-1 dual receptor agonist-1

    		GCGR Metabolic Disease
    GIP/GLP-1 dual receptor agonist-1 (compound 4) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) .
  • HY-153476A
    GIP/GLP-1 dual receptor agonist-1 sodium

    		Insulin Receptor GLP Receptor Metabolic Disease
    GIP/GLP-1 dual receptor agonist-1 (Compound 4) (sodium) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 (sodium) can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD).
  • HY-P3506
    Retatrutide
    2 Publications Verification

    LY3437943

    		 GCGR GLP Receptor Metabolic Disease
    Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .
  • HY-P3506A
    Retatrutide TFA
    2 Publications Verification

    LY3437943 TFA

    		 GLP Receptor GCGR Metabolic Disease
    Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .
  • HY-P10736
    AMG133 peptide payload

    		GCGR Metabolic Disease
    AMG133 peptide payload is a GLP-1 agonist that can be used as a peptide linker conjugate of Maridebart cafraglutide (AMG133) (HY-164535) .
  • HY-P10736A
    AMG133 peptide payload TFA

    		GCGR Metabolic Disease
    AMG133 peptide payload TFA is the TFA salt form of AMG133 peptide payload (HY-P10736). AMG133 peptide payload TFA is a GLP-1 agonist that can be used for synthesis of Maridebart cafraglutide (AMG133) (HY-164535) as a peptide linker conjugate .
  • HY-P1615
    Cenupatide

    		Transmembrane Glycoprotein Cancer
    Cenupatide (UPARANT) is a Urokinase-type plasminogen activator receptor (uPAR) inhibitor. Cenupatide has anti-angiogenic and anti-inflammatory efficacy .
  • HY-P10318
    SHR-2042

    		GLP Receptor Endocrinology
    SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
  • HY-P11042
    TE-8105

    		GLP Receptor Metabolic Disease
    TE-8105 is a GLP-1 receptor agonist that has demonstrated prolonged and potent efficacy in models of diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
  • HY-P3291
    Dapiglutide
    1 Publications Verification

    ZP7570

    		 GCGR Metabolic Disease
    Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .
  • HY-P11233
    Acmopatide

    		GLP Receptor Metabolic Disease
    Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .
  • HY-P11235
    Berobenatide

    		GLP Receptor Metabolic Disease
    Berobenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist .
  • HY-P11321
    IUB0271

    acyl-GIP

    		 Insulin Receptor Metabolic Disease
    IUB0271 (acyl-GIP) is a fatty acylated and long-acting glucose-dependent insulinotropic polypeptide (GIP). IUB0271 increases cFos neuronal activity in hypothalamic feeding centers and decreases body weight, food intake and glycemia in DIO mouse models, and these effects depend on CNS-GIPR signaling. IUB0271 can be used for type 2 diabetes mellitus (T2DM) and obesity research .
  • HY-P10959
    Macupatide

    LY3532226

    		 Insulin Receptor Metabolic Disease
    Macupatide is a gastric inhibitory peptide (GIP) receptor agonist used in anti-diabetic research .
  • HY-P10959A
    Macupatide acetate

    LY3532226 acetate

    		 Insulin Receptor Metabolic Disease
    Macupatide acetate is a gastric inhibitory peptide (GIP) receptor agonist used in anti-diabetic research .
  • HY-P10952
    Astepatide

    		Insulin Receptor GLP Receptor Metabolic Disease
    Astepatide is a gastric inhibitory peptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in anti-diabetic research .
  • HY-P3375
    Mazdutide

    IBI-362; LY-3305677; OXM-3

    		 GCGR GLP Receptor Metabolic Disease
    Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .
  • HY-P3375A
    Mazdutide TFA

    IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA

    		 GCGR GLP Receptor Metabolic Disease
    Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .
  • HY-114118
    Semaglutide
    Maximum Cited Publications
    23 Publications Verification

    		 GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
  • HY-P10591
    Olatorepatide

    Olatorepatidum

    		 Insulin Receptor GLP Receptor Metabolic Disease
    Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect .
  • HY-114118B
    Semaglutide acetate
    Maximum Cited Publications
    23 Publications Verification

    		 GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
  • HY-114118A
    Semaglutide TFA
    Maximum Cited Publications
    23 Publications Verification

    		 GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
  • HY-P11285A
    LAGIPRA peptide TFA

    Long acting GIPRA-1 TFA

    		 Insulin Receptor Metabolic Disease
    LAGIPRA peptide TFA is a long-acting GIP1R agonist. LAGIPRA peptide TFA enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide TFA has the potential for the research of type 2 diabetes .
  • HY-P11285
    LAGIPRA peptide

    Long acting GIPRA-1

    		 Insulin Receptor Metabolic Disease
    LAGIPRA peptide is a long-acting GIP1R agonist. LAGIPRA peptide enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide has the potential for the research of type 2 diabetes .
  • HY-P11271
    Ribupatide

    		Insulin Receptor GLP Receptor Metabolic Disease
    Ribupatide is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .
  • HY-P11271A
    Ribupatide TFA

    		Insulin Receptor GLP Receptor Metabolic Disease
    Ribupatide TFA is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Ribupatide TFA can be studied in antidiabetic research .
  • HY-P10956
    Colulintide

    LY3541105

    		 Amylin Receptor Metabolic Disease
    Colulintide is a functional analog of amylin that can be used in obesity research .
  • HY-P11237
    Enicepatide

    		GCGR Insulin Receptor Metabolic Disease
    Enicepatide is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .
  • HY-P5367
    5-FAM-PMDM6

    PMDM6-F

    		 Fluorescent Dye Others
    5-FAM-PMDM6 (PMDM6-F) is a biological active peptide. (PMDM6-F is a fluorescent-labeled probe for MDM2-binding assay.)
  • HY-P10032
    NN1177

    NNC9204-1177

    		 GCGR GLP Receptor Cytochrome P450 Metabolic Disease
    NN1177 is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .
  • HY-P10032A
    NN1177 TFA

    NNC9204-1177 TFA

    		 GCGR Cytochrome P450 GLP Receptor Metabolic Disease
    NN1177 (NNC9204-1177) TFA is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: